Denis Metivier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Denis Metivier has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- David Delarbre
Department of Internal Medicine, University Military Hospital Sainte-Anne, 2, Boulevard Sainte Anne, BP 600, 83000 Toulon, France
2 shared publications - Jean Baptiste Morvan
Département d'oto-rhino-laryngologie et chirurgie cervico-faciale, hôpital national d'instruction des Armées Sainte-Anne, 83800 Toulon, France; École du Val de Grâce, Académie de santé des Armées, Paris, France
2 shared publications - Juliette Thariat
Department of Radiation Oncology, Centre François Baclesse, Caen, France
2 shared publications - Laurys Boudin
Aix Marseille Univ, INSERM, CNRS, Institut Paoli-Calmettes, CRCM, Equipe labellisée Ligue Contre le Cancer, team « Predictive Oncology
2 shared publications - Pierre Yves Marcy
PolyClinics ELSAN Group, Medipole Sud, Quartier Quiez, 83189 Ollioules, France
2 shared publications - Damien Pascaud
Department of Head and Neck Surgery, University Military Hospital Sainte-Anne, 2, Boulevard Sainte Anne, BP 600, 83000 Toulon, France
1 shared publication
Latest Publications
- Open Access
- 26 November 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (12) , 9235-9241
Internal Jugular Vein Tumor Thrombus: A Tricky Question for the Thyroid Surgeon
Internal jugular vein tumor thrombus is an extremely rare condition in thyroid carcinoma, but it does exist. Correlated with greater aggressiveness with a higher incidence of distant metastases at diagnosis and a higher recurrence rate, this important prognostic element should be systematically investigated by ultrasound operators in all patients presenting with thyroid carcinoma. The patient’s follow-up must be careful. This can be a trap that surgeons must look for in their preoperative checklist. We report the case of a 58-year-old woman with an IJV thrombus associated with multiple bone metastases. She underwent successful surgical treatment, and postoperative pathology showed a poorly differentiated follicular carcinoma of the thyroid and a tumor thrombus in the internal jugular vein.
- 26 November 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (12) , 9235-9241
Open AccessInternal Jugular Vein Tumor Thrombus: A Tricky Question for the Thyroid Surgeon
Internal jugular vein tumor thrombus is an extremely rare condition in thyroid carcinoma, but it does exist. Correlated with greater aggressiveness with a higher incidence of distant metastases at diagnosis and a higher recurrence rate, this important prognostic element should be systematically investigated by ultrasound operators in all patients presenting with thyroid carcinoma. The patient’s follow-up must be careful. This can be a trap that surgeons must look for in their preoperative checklist. We report the case of a 58-year-old woman with an IJV thrombus associated with multiple bone metastases. She underwent successful surgical treatment, and postoperative pathology showed a poorly differentiated follicular carcinoma of the thyroid and a tumor thrombus in the internal jugular vein.
- Open Access
- 14 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7718-7731
Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease. Thyrosine kinase inhibitors, especially lenvatinib and immune checkpoint inhibitors such as pembrolizumab, are emerging drugs for ATC. Few studies have reported the efficacity of pembrolizumab and lenvatinib association, resulting in its frequent off-label use. In this review, we discuss rationale efficacy and safety evidence for the association of lenvatinib and pembrolizumab in ATC. First, we discuss preclinical rationale for pembrolizumab monotherapy, lenvatinib monotherapy and synergistic action of pembrolizumab and lenvatinib in the metastatic setting. We also discuss clinical evidence for immunotherapy and pembrolizumab in ATC through the analysis of studies evaluating immunotherapy, lenvatinib and pembrolizumab lenvatinib association in ATC. In addition, we discuss the safety of this association and potential predictive biomarkers of efficiency.
- 14 October 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (10) , 7718-7731
Open AccessRationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease. Thyrosine kinase inhibitors, especially lenvatinib and immune checkpoint inhibitors such as pembrolizumab, are emerging drugs for ATC. Few studies have reported the efficacity of pembrolizumab and lenvatinib association, resulting in its frequent off-label use. In this review, we discuss rationale efficacy and safety evidence for the association of lenvatinib and pembrolizumab in ATC. First, we discuss preclinical rationale for pembrolizumab monotherapy, lenvatinib monotherapy and synergistic action of pembrolizumab and lenvatinib in the metastatic setting. We also discuss clinical evidence for immunotherapy and pembrolizumab in ATC through the analysis of studies evaluating immunotherapy, lenvatinib and pembrolizumab lenvatinib association in ATC. In addition, we discuss the safety of this association and potential predictive biomarkers of efficiency.